Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

NCT ID: NCT01828294

Last Updated: 2019-04-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2017-12-31

Brief Summary

The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes the administration of intravenous immunoglobulin (IVIG), which is a plasma protein that is given to help maintain adequate antibody levels to prevent infections and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and thighs) will be better tolerated for patients with Myasthenia Gravis.

Detailed Description

The study is a pilot study to ascertain the feasibility and tolerability of subcutaneous immunoglobulin (SCIG or IGSC) as a maintenance therapy for patients with non-thymomatous MG patients (MGFA class II-IV) at entry, aged 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents.

The neurologist principal investigator at each site will have the overall responsibility for study performance is designated the medical coordinator (MC). The MC will assess patients from the sites clinic populations and identify potential subjects for inclusion and exclusion criteria. Once a subject is identified and provided informed consent to participate the Visit Schedule will be initiated.

At the initial visit the MC will perform the acetylcholine receptor antibody level, and record the prednisone and anticholinesterase doses. The MC will be responsible for assessment of adverse events. The research coordinator will arrange for the initial laboratory testing at the patient's local Quest, where the blood will be drawn. Baseline lab tests to be done will include IgA level to evaluate for deficiency, IgG level, CBC, AchR antibody, pregnancy tests in women, LFT's, PT/PTT and BUN/Creatinine. The patient will complete the SF-36 quality of life, MG, and MGFA ADL The research coordinator will be responsible for training subjects in performance of IGSC infusion. Subjects will have outpatient clinic assessments in one week and then monthly for the remainder of the study. Patients will receive 2gms/kg divided over 4 weeks initially and then will be given 250mgs/kg/wk for total of 6 months. This is similar to the standard IV treatment for patients which is 2 gm/kg given over 2-5 days for the initial dose. After the initial dose, a patient is started on monthly IV maintenance dose of 1 gm/kg each month given over 1-3 days.

The subject will be evaluated monthly for assessment of whether minimal manifestation (MM) status has been reached, which then allows reduction of corticosteroids by 5mg or more if clinically indicated. The MC will record adverse events and symptoms. The dose of anticholinesterase drugs will be decreased at the discretion of the MC. The prednisone dose will be decreased unless the MM status is lost; in that situation the prednisone dose will be increased 10mg every 2 weeks until the MM is again achieved. Titration of the prednisone and cholinesterase inhibitor medications will be at the discretion of the physician and will be based on the patient's symptoms as measured by symptoms and examination, leading to a determination of the MM. The patient will complete the SF-36 quality of life assessment.

Conditions

Myasthenia Gravis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Study Population

Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.

Group Type: OTHER

Subcutaneous immunoglobulins

Intervention Type: DRUG

Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.

Interventions

Subcutaneous immunoglobulins

Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.

Intervention Type: DRUG

Other Intervention Names

Hizentra

Eligibility Criteria

Inclusion Criteria

1. AChR Ab positive myasthenia gravis (acetylcholine receptor antibody).

2. Age 18-80 years.

3. MGFA Classification II-IV (The scale used to determine the severity of symptoms of MG).

4. Receiving > or equal 30mg of Prednisone per day.

5. No new MG-specific treatments in prior 3 months.

6. Willingness to participate in study protocol.

7. QMG > 10 (quantitative myasthenia gravis score: the sum of grades given for symptoms of MG).

8. Treatment with any immunomodulator > than or equal to 3 months prior to trial initiation.

Exclusion Criteria

1. IgA deficiency (a major class of immunoglobulins found in serum and external body secretions such as saliva, tears, and sweat as well as in the gastrointestinal, respiratory, and genitourinary tracts).

2. Previous thromboembolic events, including deep vein thrombosis, stroke and myocardial infarction

3. MGFA Class I, IV (if patient requires hospitalization) or V

4. History of thymoma

5. Thymectomy in previous year or planning to undergo thymectomy in next six months

6. Pregnancy or lactation; unwillingness to avoid pregnancy

7. Serious concurrent medical, neurological or psychiatric condition that would interfere with IGSC administration or subsequent clinical assessments

8. Unwillingness or incapacity to participate, agree to necessary follow-up visits, or give written and informed consent

9. Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin or to components of Hizentra, such as polysorbate 80, or patients with hyperprolinemia because it contains the stabilizer L-proline

10. Cholinesterase inhibitor no more than 240 mg/day

11. Body weight greater than 120 kg.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSL Behring

INDUSTRY

Sponsor Role: collaborator

St. Louis University

OTHER

Sponsor Role: lead

Responsible Party

Ghazala Hayat

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ghazala Hayat, M.D.

Role: PRINCIPAL_INVESTIGATOR

St. Louis University

Jafar Kafaie, M.D.

Role: PRINCIPAL_INVESTIGATOR

St. Louis University

Locations

George Washington University

Washington D.C., District of Columbia, United States

Saint Louis University

St Louis, Missouri, United States

Countries

United States

Other Identifiers

17005

Identifier Type: -

Identifier Source: org_study_id